CA2674717C - Use of d-ribose to treat cardiac arrhythmias - Google Patents

Use of d-ribose to treat cardiac arrhythmias Download PDF

Info

Publication number
CA2674717C
CA2674717C CA2674717A CA2674717A CA2674717C CA 2674717 C CA2674717 C CA 2674717C CA 2674717 A CA2674717 A CA 2674717A CA 2674717 A CA2674717 A CA 2674717A CA 2674717 C CA2674717 C CA 2674717C
Authority
CA
Canada
Prior art keywords
ribose
grams
atrial fibrillation
heart
cardiac arrhythmias
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2674717A
Other languages
English (en)
French (fr)
Other versions
CA2674717A1 (en
Inventor
James D. Herrick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioenergy Inc
Original Assignee
Bioenergy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioenergy Inc filed Critical Bioenergy Inc
Publication of CA2674717A1 publication Critical patent/CA2674717A1/en
Application granted granted Critical
Publication of CA2674717C publication Critical patent/CA2674717C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA2674717A 2007-01-23 2008-01-23 Use of d-ribose to treat cardiac arrhythmias Active CA2674717C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88194007P 2007-01-23 2007-01-23
US60/881,940 2007-01-23
PCT/US2008/000845 WO2008091618A1 (en) 2007-01-23 2008-01-23 Use of d-ribose to treat cardiac arrhythmias

Publications (2)

Publication Number Publication Date
CA2674717A1 CA2674717A1 (en) 2008-07-31
CA2674717C true CA2674717C (en) 2015-10-13

Family

ID=39264528

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2674717A Active CA2674717C (en) 2007-01-23 2008-01-23 Use of d-ribose to treat cardiac arrhythmias

Country Status (10)

Country Link
US (1) US8101581B2 (enExample)
EP (1) EP2120968B1 (enExample)
JP (1) JP5396387B2 (enExample)
CN (1) CN101588807B (enExample)
AT (1) ATE487485T1 (enExample)
BR (1) BRPI0806231A2 (enExample)
CA (1) CA2674717C (enExample)
DE (1) DE602008003411D1 (enExample)
ES (1) ES2352154T3 (enExample)
WO (1) WO2008091618A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119933A1 (en) * 2000-07-28 2002-08-29 Butler Terri L. Compositions and methods for improving cardiovascular function
WO2008091618A1 (en) 2007-01-23 2008-07-31 Bioenergy, Inc. Use of d-ribose to treat cardiac arrhythmias
US20100055206A1 (en) * 2008-04-02 2010-03-04 St Cyr John A Use of ribose in first response to acute myocardial infarction
EP4241838A3 (en) 2016-02-01 2023-12-20 Bioenergy Life Science, Inc. Use of ribose for treatment of subjects having congestive heart failure

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4719201A (en) 1985-02-07 1988-01-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia
US4605644A (en) 1985-02-07 1986-08-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia employing ribose and adenine
US4824660A (en) 1985-06-06 1989-04-25 Paul S. Angello Method of determining the viability of tissue in an organism
DE4228215A1 (de) * 1992-08-25 1994-03-03 Pliml Wolfgang Verwendung von Ribose zur Herstellung eines Arzneimittels zur Behandlung von Leistungsschwächen des Körpers, insbesondere von Organinsuffizienzen
RU2127548C1 (ru) * 1996-06-26 1999-03-20 Алабовский Владимир Владимирович Способ коронарографии в эксперименте
DE19650754A1 (de) * 1996-12-06 1998-06-10 Wolfgang Dr Pliml Ribose und Schlaganfall
US6218366B1 (en) 1998-06-19 2001-04-17 Bioenergy, Inc. Method for raising the hypoxic threshold
US6159942A (en) 1998-06-19 2000-12-12 Bioenergy, Inc. Compositions for increasing energy in vivo
US20020119933A1 (en) 2000-07-28 2002-08-29 Butler Terri L. Compositions and methods for improving cardiovascular function
US6429198B1 (en) 1999-04-12 2002-08-06 Bioenergy Inc. Compositions for increasing athletic performance in mammals
US6534480B2 (en) 1999-06-17 2003-03-18 Bioenergy Inc. Compositions for increasing energy in vivo
US6339716B1 (en) 1999-09-24 2002-01-15 Bioenergy Inc. Method for determining viability of a myocardial segment
US6159943A (en) 1999-09-24 2000-12-12 Bioenergy, Inc. Use of ribose to prevent cramping and soreness in muscles
US6511964B2 (en) 1999-09-24 2003-01-28 Bioenergy, Inc. Method for treating acute mountain sickness
US6703370B1 (en) 1999-10-27 2004-03-09 Bioenergy, Inc. Use of ribose to treat fibromyalgia
DE10085291T1 (de) 1999-12-21 2003-05-08 Bioenergy Inc Zusammensetzungen für die Lagerung von Blutplättchen
EP1282424A1 (en) 2000-01-07 2003-02-12 Bioenergy Inc. compositions for enhancing the immune response
AU2001229672A1 (en) 2000-01-20 2001-07-31 Bioenergy Inc. Use of ribose supplementation for increasing muscle mass and decreasing body fatin humans
US6420342B1 (en) 2000-05-08 2002-07-16 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof
IT1317043B1 (it) * 2000-06-14 2003-05-26 Sigma Tau Healthscience Spa Integratore alimentare potenziante il metabolismo energeticomuscolare, comprendente una alcanoil l-carnitina e ribosio.
US20030212006A1 (en) 2002-05-13 2003-11-13 Seifert John G. Method for reducing free radical formation in healthy individuals undergoing hypoxic exercise and medical conditions with increased oxygen free radicals
US8486859B2 (en) 2002-05-15 2013-07-16 Bioenergy, Inc. Use of ribose to enhance plant growth
US7687468B2 (en) 2003-05-14 2010-03-30 Viacell, LLC. Rejuvenation of stored blood
US8759315B2 (en) 2003-05-14 2014-06-24 Viacell, Llc Methods for rejuvenating
US20040229205A1 (en) 2003-05-16 2004-11-18 Ericson Daniel G. Compositions for the storage of platelets
ES2388859T3 (es) 2004-01-14 2012-10-19 Ribocor, Inc. Uso de ribosa para la recuperación de la anestesia
US20100099630A1 (en) 2004-04-29 2010-04-22 Maccarter Dean J Method for improving ventilatory efficiency
WO2005107768A2 (en) 2004-04-29 2005-11-17 Bioenergy, Inc. Method for improving ventilatory efficiency
ATE509624T1 (de) * 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
US8835396B2 (en) 2006-12-15 2014-09-16 Bioenergy, Inc. Method and compositions for improving pulmonary hypertension
WO2008091618A1 (en) 2007-01-23 2008-07-31 Bioenergy, Inc. Use of d-ribose to treat cardiac arrhythmias
US20080312169A1 (en) 2007-03-20 2008-12-18 Clarence Albert Johnson Cosmetic use of D-ribose
US20090197819A1 (en) 2007-03-20 2009-08-06 Clarence Albert Johnson Compositions for improving and repairing skin
US20090232750A1 (en) 2008-03-13 2009-09-17 St Cyr John A Compositions for indoor tanning
US20100055206A1 (en) 2008-04-02 2010-03-04 St Cyr John A Use of ribose in first response to acute myocardial infarction
US20090286750A1 (en) 2008-05-16 2009-11-19 Kasubick Robert V Use of ribose in lessening the clinical symptoms of aberrant firing of neurons

Also Published As

Publication number Publication date
DE602008003411D1 (de) 2010-12-23
US8101581B2 (en) 2012-01-24
CA2674717A1 (en) 2008-07-31
EP2120968A1 (en) 2009-11-25
ES2352154T3 (es) 2011-02-16
EP2120968B1 (en) 2010-11-10
JP5396387B2 (ja) 2014-01-22
US20080176809A1 (en) 2008-07-24
CN101588807B (zh) 2012-07-04
BRPI0806231A2 (pt) 2011-09-06
CN101588807A (zh) 2009-11-25
WO2008091618A1 (en) 2008-07-31
WO2008091618A8 (en) 2010-04-01
JP2010526884A (ja) 2010-08-05
ATE487485T1 (de) 2010-11-15

Similar Documents

Publication Publication Date Title
Sloman et al. Propranolol (Inderal) in persistent ventricular fibrillation
FI4243825T3 (fi) Omekamtiivimekarbiili sydämen vajaatoiminnan hoitoon valikoiduilla potilasryhmillä
KR20110026422A (ko) 영구적 심방 세동의 예방을 위한 드로네다론
JP2019206562A5 (enExample)
Wolk et al. The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propranolol or propafenone
Franga et al. Recurrent asystole resulting from high cervical spinal cord injuries
CA2674717C (en) Use of d-ribose to treat cardiac arrhythmias
Sandler et al. Use of oxprenolol in cardiac arrhythmias associated with acute myocardial ischaemia
Herre et al. Polymorphic ventricular tachycardia and ventricular fibrillation due to N-acetyl procainamide
Gogelein et al. HMR 1098: An inhibitor of cardiac ATP-sensitive potassium channels
Hooqenhuvze et al. Acute effects of intravenous amiodarone in patients with complex ventricular dysrhythmias
Aronow Optimal management of older patients with atrial fibrillation
Bashour et al. Effective management of the long QT syndrome with amiodarone
Vavricka et al. Brugada syndrome
Humphreys et al. Arrhythmias and their Management
RU2320328C2 (ru) Способ лечения персистирующей формы фибрилляции предсердий
RU2148999C1 (ru) Применение этимизола в качестве антиаритмического средства для предупреждения желудочковой экстрасистолии у больных ибс
Khaksar et al. Protective effects of the combination of exercise and gallic acid supplementation on cardiac system in CaCl2-induced arrhythmias model in rats
Sadeghian et al. Short QT syndrome and idiopathic ventricular tachycardia in a 28-year-old young man: a potential disease-specific link?
Chen et al. Left cervicothoracic sympathetic ganglionectomy with thoracoscope for the treatment of idiopathic long QT syndrome
Schober Medical treatment of tachyarrhythmias.
Bayley Long-term ventricular pacing in treatment of sinoatrial block
Sulke et al. Acceleration of conduction within an accessory pathway with propafenone
Hagens et al. Rate or rhythm control for persistent atrial fibrillation
CN118304374A (zh) 一种组合物在制备治疗心动过速和/或瓣膜反流药物中的应用

Legal Events

Date Code Title Description
EEER Examination request
EEER Examination request

Effective date: 20121220

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250109

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250109